Assessment of patient-reported outcome measures in the surgical treatment of patients with gastric cancer

Jennifer Straatman1 · Nicole van der Wielen1 · Pieter J. Joosten1 · Caroline B. Terwee2 · Miguel A. Cuesta1 · Elise P. Jansma3 · Donald L. van der Peet1

Received: 4 May 2015 / Accepted: 6 July 2015 / Published online: 27 August 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract
Background Gastric cancer is responsible for 10 % of all cancer-related deaths worldwide. With improved operative techniques and neo-adjuvant therapy, survival rates are increasing. Outcomes of interest are shifting to quality of life (QOL), with many different tools available. The aim of this study was to assess which patient-reported outcome measures (PROMs) are used to measure QOL after a gastrectomy for cancer.

Methods A comprehensive search was conducted for original articles investigating QOL after gastrectomy. Two authors independently selected relevant articles, conducted clinical appraisal and extracted data (P.J. and J.S.).

Results Out of 3414 articles, 26 studies were included, including a total of 4690 patients. These studies included ten different PROMs, which could be divided into generic, symptom-specific and disease-specific questionnaires. The EORTC and the FACT questionnaires use an oncological overall QOL module and an organ-specific module. Only one validation study regarding the use of the EORTC after surgery for gastric cancer was available, demonstrating good psychometric properties and clinical validity.

Conclusions A great variety of PROMs are being used in the measurement of QOL after surgery for gastric cancer. A questionnaire with a general module along with a disease-specific module for the assessment of QOL seems most desirable, such as the EORTC and the FACT with their specific modules. Both are developed in different treatment modalities, such as in surgical patients. EORTC is the most widely used questionnaire and therefore allows for comparison of new studies to existing data. Future studies are needed to assess content validity in surgical gastric cancer patients.

Keywords Quality of life · Gastric cancer · Gastrectomy · PROMs

Gastric cancer is responsible for 10 % of all cancer-related deaths worldwide, with the highest incidences in Eastern Asia, Eastern Europe and South America [1]. Although multiple treatment modalities exist, surgical resection of the primary tumour and regional lymph nodes is still the only curative treatment available for gastric cancer [2]. Currently, the 5-year survival rate after oesophageal resection is approximately 20 % [3]. With the implementation of minimally invasive techniques and additional treatments such as neo-adjuvant chemotherapy, survival rates have improved and an according number of long-term survivors exists [4–6]. Laparoscopic techniques have been shown to improve quality of life sooner after surgery [7].

With increasing survival and decreased morbidity, a shift in interest of outcome parameters is seen from survival and morbidity rates to the impact of radical gastrectomy and chemoradiotherapy on patient-reported outcomes, such as quality of life (QOL) [8]. Information about QOL outcomes should be an important outcome parameter in research regarding the optimal treatment for gastric cancer.

The World Health Organization (WHO) defined QOL as an individuals’ perception of their position in life in the
cultural context and in the value system in which they live and in relation to their goals, expectations, standards and concerns [9]. QOL data provide direct measures of benefit as perceived by the patient and may be useful in clarifying treatment preferences. Many different questionnaires are available, both validated and non-validated, to assess the quality of life [7]. Although the different instruments focus on different aspects of QOL, no consensus exists as to which instrument is optimal in the assessment of QOL after gastrectomy for gastric cancer [10]. The aim of this systematic review was to assess which PROMs are used in the assessment of QOL after surgery for gastric cancer.

Materials and methods

Literature search

To identify all relevant publications, a systematic search in the bibliographic databases PubMed, EMBASE and The Cochrane Library (via Wiley) from inception to 14 October 2014 was performed. Search terms included controlled terms from MeSH in PubMed, Emtree in EMBASE.com as well as free text terms. Free text terms were only used in The Cochrane library. Search terms expressing “stomach neoplasm” were used in combination with search terms comprising “surgery”. Moreover, an extensive search filter for finding patient-reported outcome measures was used, developed by the University of Oxford (“Appendix”). The reference list of included articles was hand-searched for relevant publications.

Selection criteria and definitions

Two authors (P.J. and J.S.) independently evaluated the search findings for potential eligibility for systematic review using the MEDLINE, EMBASE and Cochrane databases. The inclusion criteria were: (1) article published in English language; (2) only full-text articles, no abstracts or case reports were included and (3) the study had to investigate
QOL after gastric resection using questionnaires (i.e. non-structured interviews were not included). (4) Only patients with gastric carcinoma were included. Studies that described gastrointestinal stromal tumours (GIST) and benign tumours were excluded. Distal, proximal, subtotal and total gastrectomies were included. Wedge resections and local resections were excluded. Regarding surgical techniques, both open and minimally invasive procedures were included, and various reconstructive methods were included (i.e. Roux-en Y or Billroth reconstruction).

Data extraction and quality assessment

The reviewers (P.J. and J.S.) extracted the following data from each study: first author, title of the article, year of publication, type of study, type of gastrectomy, type of reconstruction, number of patients included and the PROMs used to assess QOL. All articles that were deemed suitable after full-text analysis were assessed for quality of the performed study.

Results

Study selection

Initially, the literature search of MEDLINE, EMBASE and Cochrane resulted in 4529 hits, after removal of duplicates 3414 hits remained. The articles were screened based on title and abstract by two different authors (P.J. and J.S.) independently, and this resulted in a selection of 141 articles for full-text analysis. Of these 141 articles, another 115 were excluded since they did not meet the predefined criteria as described in the methods section; 28 articles were published in another language than English; 45 references consisted only of conference abstracts; 39 articles included a different subject; a final three articles were excluded because they did not use questionnaires but self-reported interviews for QOL assessment. Twenty-six articles remained for further analysis. A flow chart of the article selection is depicted in Fig. 1.
Table 2 Description of retrospective cohort studies

| Study                | Country | Study type | Patient (n) | Aim                                                                 | QOL instruments                  | Follow-up                          |
|---------------------|---------|------------|-------------|----------------------------------------------------------------------|----------------------------------|-------------------------------------|
| Amemiya et al. [36] | Japan   | Retrospective | 223         | Patients older than 75 years                                         | SF-12, EQ-5D                     | Baseline, 1.3 and 6 months          |
| Rausei et al. [37]  | Italy   | Retrospective | 103         | Total versus subtotal resection, lymphadenectomy and multivisceral resection | EORTC QLQ-C30, EORTC QLQ-STO22   | Mean follow-up 81 ± 80.7 months     |
| Park et al. [38]    | Korea   | Retrospective | 275         | Total versus subtotal/distal resection                              | EORTC QLQ-C30, EORTC QLQ-STO22   | Baseline, 3, 6, 9, 12, 18 and 24 months |
| Díaz de Liaño et al. [39] | Spain  | Retrospective | 54          | Total versus subtotal gastrectomy and D1 versus D2 lymphadenectomy | EORTC QLQ-C30                   | 49 months (range 41–89)            |
| Buhl et al. [40]    | Germany | Retrospective | 104         | Distal versus total gastrectomy with Roux-en Y or pouch              | Spitzer index                    | 12 months                          |
| Bae et al. [41]     | Korea   | Retrospective | 391         | Total versus subtotal                                                | EORTC QLQ-C30, EORTC QLQ-STO22   | 27.5 ± 3.3 months                   |
| Huang et al. [42]   | Taiwan  | Retrospective | 51          | Total versus subtotal gastrectomy, early versus late stage          | EORTC QLQ-C30, EORTC QLQ-STO22   | 17 months (range 6–24 months)      |
| Soo Lee et al. [43] | Korea   | Retrospective | 80          | Open versus laparoscopy-assisted distal gastrectomy                 | EORTC QLQ-C30, EORTC QLQ-STO22   | 6 months to 5 year range           |
| Tyrvainen et al. [44]| Finland | Retrospective | 172         | QOL in long-term survivors after total gastrectomy                  | SF-36, 15D                       | Median 9 (6–19) years              |
| Nakamura et al. [11]| Japan   | Retrospective | 883         | Development and validation of DAUGS                                 | DAUGS20                          | 3 and 6 months, 1, 2 and 3 years    |
| Nakamura et al. [45]| Japan   | Retrospective | 165         | Evaluate DAUGS in patients after gastric resection                  | DAUGS32                          | 3–6 months, 6–1 year, 1–2 years, 1–3 years |
| Kong et al. [46]    | Korea   | Retrospective | 272         | Chronological change of QOL after gastrectomy                      | EORTC QLQ-C30, EORTC QLQ-STO22   | Baseline, 3, 6, 9 and 12 months     |
| Soo Lee et al. [47] | Korea   | Retrospective | 143         | QOL 5 years or more after total gastrectomy                        | EORTC QLQ-C30, EORTC QLQ-STO22   | Mean 89.3 (range 66–201) months    |
| Soo Lee et al. [48] | Korea   | Retrospective | 126         | QOL of long-term survivors after distal subtotal gastrectomy        | EORTC QLQ-C30, EORTC QLQ-STO22   | 5 years                             |

Study characteristics

Twenty-six articles were included for full-text analysis, of which twelve articles were prospective cohort studies, six of which were randomized controlled trials, and fourteen were retrospective cohort studies with prospective QOL assessment, including a total of 4690 patients. One study was a development and validation study [11]. There was great dispersion in follow-up data, ranging from 6 months to 5 years. An overview of the included articles is given in Table 1 for prospective articles and Table 2 for retrospective studies.

The quality-of-life instruments

Twenty-six full-text articles were assessed regarding QOL following surgical procedures for gastric cancer. In these articles, a total of ten different PROMs were described. Different instruments focused on different dimensions of the QOL (i.e., physical, functional, social and emotional function).

The PROMs could be divided into separate categories, as given in Table 3. First four generic instruments were used, i.e., the Short Form-12 (SF-12), Sickness Impact Profile (SIP), Spitzer index and EuroQol-5D (EQ-5D). These instruments were used to compare results across
| Questionnaires | Target population | Dimensions (number of items) | Ease of scoring and administration (range of scores) | Number of studies |
|----------------|-------------------|------------------------------|-----------------------------------------------------|------------------|
| **Generic**    |                   |                              |                                                     |                  |
| SIP [49]       | Very broad, tested in non-, in- and out-patient with different illnesses and different severities | Sleep and rest (7) Eating (9) Work (9) Home management (10) Recreation and pastimes (8) Ambulation (10) Mobility (10) Body care and movement (23) Social interaction (20) Alertness behaviour (10) Emotional behaviour (9) Communication (9) Total = 136 | Easy (0–136) | 1 |
| SF-12 [50]     | General population | Physical functioning (2) Role physical (2) Bodily pain (1) General health (1) Vitality (1) Social functioning (1) Role emotional (2) Mental health (2) | Easy (12–47) | 1 |
| EQ-5D [51]     | General population | Mobility Self-care Usual activities Pain/discomfort Anxiety/depression | Easy (0–100 per dimension) | 1 |
| The Spitzer QOL index [13] | Cancer patients | Activity Daily living Health Social support Outlook | Easy (0–2 per question) (0–10) | 3 |
| **Symptom focused** |                   |                              |                                                     |                  |
| GIQLI [14, 52] | Developed in patients with benign or malignant disorders of the oesophagus, stomach, gallbladder, pancreas, small intestine, colon, and rectum. And developed in patients who underwent a laparoscopic cholecystectomy | Physical well-being (10) Mental well-being (5) Gastrointestinal symptoms (16) Single items (5) | Easy (0–4 per question) (0–144) | 1 |
| GSRS [15, 53]  | Developed for irritable bowel syndrome and peptic ulcer disease. Later validated in upper gastrointestinal patient | Abdominal pain syndrome Reflux syndrome Indigestion syndrome Diarrhoea syndrome Constipation syndrome | Easy (0–3 per question) (0–45) | 2 |
| Questionnaires         | Target population                                                                 | Dimensions (number of items)                                                                 | Ease of scoring and administration (range of scores) | Number of studies |
|------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------------------------------------------|-------------------|
| Cancer specific        |                                                                                    |                                                                                             |                                                      |                   |
| EORTC QLQ-C30 [22]     | Cancer patients (developed in lung cancer patients)                                | Global health (2)                                                                            | Easy (1–4 per question)                              | 15                |
|                        |                                                                                     | Functional scales                                                                           |                                                      |                   |
|                        |                                                                                     | Physical (5)                                                                                |                                                      |                   |
|                        |                                                                                     | Role (2)                                                                                   |                                                      |                   |
|                        |                                                                                     | Cognitive (2)                                                                               |                                                      |                   |
|                        |                                                                                     | Emotional (4)                                                                               |                                                      |                   |
|                        |                                                                                     | Social (2)                                                                                 |                                                      |                   |
|                        |                                                                                     | Symptom scales                                                                              |                                                      |                   |
|                        |                                                                                     | Fatigue (3)                                                                                |                                                      |                   |
|                        |                                                                                     | Pain (2)                                                                                   |                                                      |                   |
|                        |                                                                                     | Nausea and vomiting (2)                                                                     |                                                      |                   |
|                        |                                                                                     | Single items (6)                                                                            |                                                      |                   |
| FACT-G [19]            | General cancer, developed in breast, lung and colorectal cancer                    | Physical (7)                                                                                | Easy (1–4 per question)                              | 1                 |
|                        |                                                                                     | Social/family (7)                                                                           |                                                      |                   |
|                        |                                                                                     | Emotional (6)                                                                               |                                                      |                   |
|                        |                                                                                     | Functional (7)                                                                             |                                                      |                   |
| Gastric cancer specific|                                                                                    |                                                                                             |                                                      |                   |
| EORTC QLQ-STO22 [23]   | Patients with gastric cancer undergoing surgery, chemo- or chemoradiotherapy in curative or palliative setting | Five scales                                                                                 | Easy (1–4 per question)                              | 12                |
|                        |                                                                                     | Dysphagia (4)                                                                               |                                                      |                   |
|                        |                                                                                     | Eating restrictions (5)                                                                     |                                                      |                   |
|                        |                                                                                     | Pain (3)                                                                                    |                                                      |                   |
|                        |                                                                                     | Reflux (3)                                                                                 |                                                      |                   |
|                        |                                                                                     | Anxiety (3)                                                                                |                                                      |                   |
|                        |                                                                                     | Three single items                                                                          |                                                      |                   |
|                        |                                                                                     | Dry mouth (1)                                                                               |                                                      |                   |
|                        |                                                                                     | Body image (1)                                                                             |                                                      |                   |
|                        |                                                                                     | Hair loss (2)                                                                              |                                                      |                   |
| FACT-Ga [20]           | Gastric cancer (adenocarcinoma), gastrectomy, chemo and radiotherapy               | Gastric cancer subscale (19)                                                               | Easy (0–4 per question)                              | 1                 |
| Postoperative          |                                                                                    |                                                                                             |                                                      |                   |
| Korenaga’s score [25]  | Treatment-specific after gastrectomy                                                | Single items (14)                                                                           | Easy (0–2 per question)                              | 1                 |
| DAUGS20 [11]           | Developed to assess postoperative dysfunction after surgery for gastric and oesophageal carcinoma | Single items (20)                                                                          | Easy (1–5 per question)                              | 2                 |
|                        |                                                                                     | Limited activity due to decreased food consumption                                          |                                                      |                   |
|                        |                                                                                     | Reflux                                                                                     |                                                      |                   |
|                        |                                                                                     | Dumping                                                                                    |                                                      |                   |
|                        |                                                                                     | Nausea and vomiting                                                                         |                                                      |                   |
|                        |                                                                                     | Deglutition difficulty                                                                      |                                                      |                   |
|                        |                                                                                     | Pain                                                                                       |                                                      |                   |
|                        |                                                                                     | Difficulty in stool formation and passage                                                  |                                                      |                   |

*SIP* Sickness Impact Profile, *SF-12* The 12-item Short Form Healthy Survey, *EQ-5D* EuroQoL-5D, *GIQLI* Gastrointestinal Quality of Life Index, *GSRS* Gastrointestinal Symptom Rating Scale, *EORTC QLQ* European Organization for Research and Treatment QOL Questionnaire, *FACT-G* Functional Assessment of Cancer Therapy—General, *DAUGS* Dysfunction After Upper Gastrointestinal Surgery, *FACT-Ga* Functional Assessment of Cancer Therapy for patients with Gastric Cancer
different conditions of health. These questionnaires are developed and validated to measure QOL in a general population. The Spitzer index is a global health assessment tool, which assess activity, daily living, health, support system and outlook. No symptom- or treatment-specific questions are included in this questionnaire [12, 13]. The SF-12, SIP and EQ-5D have all been used once, and three out of the twenty studies have used the Spitzer index.

Secondly, symptom-specific questionnaires were used, namely the Gastrointestinal Quality of Life Index (GIQLI) and the Gastrointestinal Symptom Rating Scale (GSRS). The GIQLI is developed in patients with benign and malignant disorders [14]. The GSRS was initially developed in patients with irritable bowel disease and not specifically designed for oncological or postoperative patients [15]. Only one study assessed QOL with the GIQLI score [16]. The GSRS score was used in two studies and allowed for overall assessment and of assessment of the individual items [17, 18]. GIQLI and GSRS are specifically designed for gastrointestinal symptoms, not for overall QOL.

A third group consists of disease-specific questionnaires. The Functional Assessment of Cancer Therapy (FACT) questionnaires consist of a general health module (FACT-G), and disease-specific modules can be added, such as FACT-Ga for gastric cancer [19, 20], thus allowing for the assessment of overall QOL and assessment of disease-specific symptoms by adding the appropriate module. The FACT-Ga is developed in patients with gastric cancer who underwent different treatment modalities, such as gastrectomy, chemotherapy and radiotherapy [20]. One study has used the FACT questionnaire [21].

The European Organisation for Research and Treatment of Cancer (EORTC) questionnaires work in a similar fashion, consisting of a general health questionnaire, the EORTC QLQ-C30, which is aimed specifically at cancer patients [22]. Disease-specific modules can be added, such as the EORTC QLQ-STO22 for gastric cancer. The EORTC QLQ-STO22 is developed in patients with gastric cancer who underwent different treatment modalities, such as surgery, chemo- or chemoradiotherapy in curative or palliative setting [23, 24]. The EORTC QLQ-STO22 and the FACT-Ga are site-specific questionnaires that are related to gastric cancer [20, 23]. Fifteen out of twenty-six studies have used the EORTC QLQ-C30 of which twelve studies also included the EORTC QLQ-STO22 module.

Only one validation study was identified, which assessed the use of the STO22 module in patients who were operated in curative or palliative setting. The module was found to have a good internal consistency (Cronbach’s alpha’s >0.7) and was deemed reliable and sensitive to changes in both individual patient status and differences between patient groups [23].

Postoperative patients are considered a different entity in the DAUGS20 and Korenaga’s score, and these questionnaires focus specifically on patients following gastrectomy for cancer [11]. The questionnaires measure treatment-specific symptoms, such as appetite, swallowing, heartburn and diarrhoea [25, 26]. The Dysfunction After Upper Gastrointestinal Surgery (DAUGS20) questionnaire was originally designed in gastric and oesophageal cancer patients who had undergone surgery. The DAUGS is designed to measure QOL postoperative, and no baseline measurement is included [26]. An overview of the different PROMs is provided in Table 3.

Discussion

The here-presented systematic review aimed to review what PROMs are available in assessing the QOL in patients with gastric cancer who undergo gastric resection. Ten PROMs were identified in 26 studies regarding different surgical techniques or comparison of different treatment modalities.

Gastrectomy with radical resection margins of 5 cm around the tumour along with adequate lymphadenectomy is currently the only curative therapy available in gastric cancer [27]. Overall QOL and even separate domains of QOL may differ between different treatment modalities. Question remains whether surgical patients should be considered a separate entity, and whether questionnaires should be developed or adapted for patients undergoing gastrectomy. In an optimal setting, the PROMs should allow for overall assessment of QOL, along with specific modules to assess specific effects associated with the disease and treatment [28].

The DAUGS20 and Korenaga’s score consider surgical patients to be a different entity. These questionnaires are specifically aimed at the postoperative patient who had surgery for gastric cancer [25, 29]. No validation studies regarding these questionnaires were available. DAUGS20 and Korenaga’s score are not developed for overall QOL assessment and are preferably to be used alongside a general QOL PROM [26, 30]. Since the questionnaires aim specifically at the postoperative patient, they do not allow for comparison of QOL among different treatment modalities such as chemotherapy and radiotherapy. They do allow for comparison of QOL among different surgical techniques.

The EORTC and FACT questionnaires consider gastric cancer patients as a whole. Both the EORTC and FACT questionnaires consist of a general cancer QOL module to which organ-specific module can be added (EORTC QLQ-STO22 and FACT-Ga), allowing for general and disease-specific QOL assessment between different treatment modalities. Both questionnaires were developed in patients with gastric cancer undergoing different treatment modalities, including surgery. With regard to comparability and reproducibility, the EORTC was used more often and
might therefore allow for comparison to conducted studies, taking into account the heterogeneity in research questions, time points of QOL measurement and follow-up.

Fourteen (54%) of the included studies consisted of retrospective cohort studies. Only six randomized studies were available. Differences in study design, endpoints, patient groups, surgical techniques and time points in the studies further limited assessment and pooling of data. No validation studies were available for the use of these PROMs in patients undergoing surgery for gastric cancer; hence, comparison of the performance of the different PROMs with regard to validity, internal consistency and discriminative ability was not possible.

Future research should focus on content validity of the used questionnaires in postgastroctomy patients in order to assess whether all the important domains are truly assessed and no items are missing. In order to further assess the use of PROMs in treatment of individual patients, our project group is currently aiming to develop a core outcome set of patient-reported outcomes in gastric cancer patients.

In conclusion, in the assessment of QOL in surgical gastric cancer patients, a great variety of PROMs are being used. A questionnaire with a general module to assess overall QOL, which can be supplemented with disease-specific modules allowing for the assessment or QOL of different treatment modalities, seems to be most desirable. With regard to current practice, the EORTC QLQ-C30 with STO22 module was developed in gastric cancer patients with different treatments, and it is used most widely, allowing for comparison of new data to studies that were already conducted. Future research should assess the need for treatment-specific modules.

Compliance with ethical standards

Disclosures The authors, Jennifer Straatman, Nicole van der Wielen, Pieter J. Joosten, Caroline B. Terwee, Miguel A. Cuesta, Elise P. Jansma and Donald L. van der Peet, declare that they have no conflict of interest

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Appendix

| Search | PubMed Query 17 November 2014 | Items found |
|--------|-------------------------------|-------------|
| #5     | Search “Stomach Neoplasms”[Mesh] OR Stomach Neoplasm*[tiab] OR Gastric Neoplasm*[tiab] OR Gastric Cancer*[tiab] OR Stomach carcinoma*[tiab] OR gastric carcinoma*[tiab] OR stomach tumor*[tiab] OR stomach tumour*[tiab] OR gastric tumour*[tiab] OR stomach neoplasia*[tiab] OR cardia carcinoma*[tiab] OR limitis plastic*[tiab] OR Stomach | 87062 |
| #6     | Search “gastrectomy”[MeSH] OR ((gastrectom*[tiab] OR “gastro resection”*[tiab] OR gastrectom*[ot] OR “gastro resection”*[ot] NOT medline[sh]) | 27902 |
| #7     | Search (HR-PRO*[tiab] OR HRPRO*[tiab] OR HRQL*[tiab] OR HRQol*[tiab] OR QL*[tiab] OR QoL*[tiab] OR quality of life*[tiab] OR life quality*[tiab] OR health index*[tiab] OR health indices*[tiab] OR health profile*[tiab] OR health status*[w] OR ((patient*[tiab] OR self*[tiab] OR child*[tiab] OR parent*[tiab] OR carer*[tiab] OR proxy*[tiab] AND (report*[tiab] OR reported*[tiab] OR reporting*[tiab] OR rated*[tiab] OR rating*[tiab] OR ratings*[tiab]) OR based*[tiab] OR (assessed*[tiab] OR assessment*[tiab] OR assessments*[tiab])) OR ((disability*[tiab] OR function*[tiab] OR functional*[tiab] OR functions*[tiab] OR subjective*[tiab] OR utility*[tiab] OR utilities*[tiab] OR wellbeing*[tiab] OR well being*[tiab]) AND (outcome*[tiab] OR index*[tiab] OR indices*[tiab] OR instrument*[tiab] OR instruments*[tiab] OR measure*[tiab] OR measures*[tiab] OR questionnaire*[tiab] OR questionnaires*[tiab] OR profile*[tiab] OR profiles*[tiab] OR scale*[tiab] OR scales*[tiab] OR score*[tiab] OR scores*[tiab] OR status*[tiab] OR survey*[tiab] OR surveys*[tiab])) | 1657339 |
| #8     | Search #5 AND #6 AND #7 | 1625 |
| #9     | Search PubMed Query 17 November 2014 | 1610 |
References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

2. Wu CW, Lo SS, Shen KH, Hsieh MC, Liu WH, P’Eng FK (2000) Surgical mortality, survival, and quality of life after resection for gastric cancer in the elderly. World J Surg 24:465–472

3. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ (2001) Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 72:306–313

4. Kitano S, Iso Y, Moriyama M, Sugimachi K (1994) Laparoscopy-assisted Billroth I gastroectomy. Surg Laparosc Endosc 4:146–148

5. Azagra JS, Goergen M, De Simone P, Ibanez-Aguirre J (1999) Minimally invasive surgery for gastric cancer. Surg Endosc 13:351–357

6. Cunningham D, Allum WH, Stenning SP, Johnson JV, De velde CJ, Nicholson M, Scarffe JH, Lofs FJ, Falk SJ, Iveson TJ, Smith DB, Langle RE, Verma M, Weeden S, Chua YJ (2000) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

7. Koroljka D, Sauerland S, Wood-Dauphinee S, Abbou CC, Eypasch E, Caballero MG, Lumsden MA, Millat B, Monson JR, M, Kobayashi K, Kimura Y, Kurokawa Y, Mori M, Doki Y, Ishii H, Takahashi A, Fujii H, Matsumoto Y (2003) Improved quality of life with jejunal pouch reconstruction after total gastrectomy. Am J Surg 185:150–154

8. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E, D’Haese S, Coens C, European Organisation for Research and Treatment of Cancer (2004) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 40:2260–2268

9. Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, Rosemeyer D, Johnson CD, Alderson D, Group EQoL (2001) Development of an EORTC disease-specific quality of life module for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

10. Munene G, Francis W, Garland SN, Pelletier G, Mac K, Blay J, Bottomley A, Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, Rosemeyer D, Johnson CD, Alderson D, Group EQoL (2001) Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer 37:966–971

11. Scruro B, Groza N, Oet O, Goia A, Funar J, D’Haese S, Coens C, European Organisation for Research and Treatment of Cancer (2004) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 40:2260–2268

12. Garcia SF, Cell D, Clausen SB, Flynn KE, Lad T, Sai JS, Reev BB, Smith AW, Stone AA, Weinfurt K (2007) Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 25:5106–5112

13. Takiguchi S, Yamamoto K, Hirao M, Imamura H, Fujita J, Yano M, Kobayashi K, Kimura Y, Kurokawa Y, Mori M, Doki Y, Neugbauer E, Troidl H (1995) Gastrointestinal Quality of Life Index: development, validation, and application of a new instrument. Br J Surg 82:216–222

14. Kulich KR, Madisch A, Pacini F, Pique JM, Regula J, Van Rensburg CJ, Ujsaszky L, Carlsson J, Halling K, Wulkink FK (2008) Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes 6:12

15. Horvath OP, Kalmar K, Cseke L, Poto L, Zambo K (2001) Nutritional and life-quality consequences of aboral pouch construction after total gastrectomy: a randomized, controlled study. Eur J Surg Oncol 27:558–563

16. Svedlund J, Sullivan M, Liedman B, Lendell L (1999) Long term consequences of gastrectomy for patient’s quality of life: the impact of reconstructive techniques. Am J Gastroenterol 94:438–445

17. Kono K, Iizuka H, Sekikawa T, Sugai H, Takahashi A, Fujii H, Matsutomo Y (2003) Improved quality of life with jejunal pouch reconstruction after total gastrectomy. Am J Surg 185:150–154

18. Cell DF, Tulskey DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579

19. Garland SN, Pelletier G, Lawe A, Biagioni BJ, Easaw J, Eliaszw M, Cella D, Bathe OF (2011) Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer 117:1302–1312

20. Brojazky M, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E, D’Haese S, Coens C, European Organisation for Research and Treatment of Cancer (2004) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 40:2260–2268

21. Munene G, Francis W, Garland SN, Pelletier G, Mac K, Blay J, Bottomley A, Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, Rosemeyer D, Johnson CD, Alderson D, Group EQoL (2001) Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer 37:966–971

22. Scruro B, Groza N, Oet O, Goia A, Funar J, D’Haese S, Coens C, European Organisation for Research and Treatment of Cancer (2004) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 40:2260–2268

23. Garcia SF, Cell D, Clausen SB, Flynn KE, Lad T, Sai JS, Reev BB, Smith AW, Stone AA, Weinfurt K (2007) Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 25:5106–5112

24. Takiguchi S, Yamamoto K, Hirao M, Imamura H, Fujita J, Yano M, Kobayashi K, Kimura Y, Kurokawa Y, Mori M, Doki Y, Neugbauer E, Troidl H (1995) Gastrointestinal Quality of Life Index: development, validation, and application of a new instrument. Br J Surg 82:216–222

Search PubMed Query 17 November 2014

Items found

Neoplasm*[ot] OR Gastric Neoplasm*[ot] OR Stomach Cancer*[ot] OR Gastric Cancer*[ot] OR Stomach carcinoma*[ot] OR gastric carcinoma*[ot] OR stomach tumour*[ot] OR gastric tumour*[ot] OR stomach neoplasia*[ot] OR cardia carcinoma*[ot] OR limitis plastica*[ot]
Osaka University Clinical Research Group for Gastroenterological S (2012) A comparison of postoperative quality of life and dysfunction after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: results from a multi-institutional RCT. Gastric Cancer 15:198–205

30. Korenaga D, Orita H, Okuyama T, Moriguchi S, Maehara Y, Sugimachi K (1992) Quality of life after gastrectomy in patients with carcinoma of the stomach. Br J Surg 79:248–250

31. Zieren HU, Zippe K, Zieren J, Muller JM (1998) Quality of life after surgical treatment of gastric carcinoma. Eur J Surg 164:119–125

32. Avery K, Hughes R, McNair A, Alderson D, Barham P, Blazeby J (2010) Health-related quality of life and survival in the 2 years after surgery for gastric cancer. Eur J Surg Oncol 36:148–154

33. Karanikolas PJ, Graham D, Gonen M, Strong VE, Brennan MF, Coit DG (2013) Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. Ann Surg 257:1039–1046

34. Kim AR, Cho J, Hsu YJ, Choi MG, Noh JH, Sohn TS, Bae JM, Yun YH, Kim S (2012) Changes of quality of life in gastric cancer patients after curative resection: a longitudinal cohort study in Korea. Ann Surg 256:1008–1013

35. Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi JI, Bae JM (2008) Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 248:721–727

36. Amemiya T, Oda K, Ando M, Kawamura T, Kitagawa Y, Okawa Y, Yasui A, Ike H, Shimada H, Kuroiwa K, Nimura Y, Fukata S (2007) Activities of daily living and quality of life of elderly patients after elective surgery for gastric and colorectal cancers. Ann Surg 246:222–228

37. Rausel S, Mangano A, Galli F, Rovera F, Boni L, Dionigi G, Dionigi R (2013) Quality of life after gastrectomy for cancer evaluated via the EORTC QLC-C30 and QLC-STO22 questionnaires: surgical considerations from the analysis of 103 patients. Int J Surg (London, England) 11(Suppl 1):S104–S109

38. Park S, Chung HY, Lee SS, Kwon O, Yu W (2014) Serial comparisons of quality of life after distal subtotal or total gastrectomy: what are the rational approaches for quality of life management? J Gastric Cancer 14:32–38

39. Diaz De Liano A, Oteiza Martinez F, Ciga MA, Aizcorbe M, Cobo F, Trujillo R (2003) Impact of surgical procedure for gastric cancer on quality of life. Br J Surg 90:91–94

40. Buhl K, Lehnert T, Schlag P, Herfarth C (1995) Reconstruction after gastrectomy and quality of life. World J Surg 19:558–564

41. Bae JM, Kim S, Kim YW, Ryu KW, Lee JH, Noh JH, Sohn TS, Hong SK, Park SM, You CH, Kim JH, Lee MK, Yun YH (2006) Health-related quality of life among disease-free stomach cancer survivors in Korea. Qual Life Res 15:1587–1596

42. Huang CC, Lien HH, Wang PC, Yang JC, Cheng CY, Huang CS (2007) Quality of life in disease-free gastric adenocarcinoma survivors: impacts of clinical stages and reconstructive surgical procedures. Dig Surg 24:59–65

43. Lee SS, Ryu SW, Kim IH, Sohn SS (2012) Quality of life beyond the early postoperative period after laparoscopy-assisted distal gastrectomy: the level of patient expectation as the essence of quality of life. Gastric Cancer 15:299–304

44. Tyrvainen T, Sand J, Sintonen H, Nordback I (2008) Quality of life in the long-term survivors after total gastrectomy for gastric carcinoma. J Surg Oncol 97:121–124

45. Nakamura M, Hosoya Y, Yano M, Doki Y, Miyashiro I, Kuras hina K, Morooka Y, Kishi K, Lefor AT (2011) Extent of gastric resection impacts patient quality of life: the Dysfunction After Upper Gastrointestinal Surgery for Cancer (DAUGS32) scoring system. Ann Surg Oncol 18:314–320

46. Kong H, Kwon OK, Yu W (2012) Changes of quality of life after gastric cancer surgery. J Gastric Cancer 12:194–200

47. Lee SS, Chung HY, Kwon OK, Yu W (2014) Quality of life in cancer survivors 5 years or more after total gastrectomy: a case-control study. Int J Surg (London, England) 12:700–705

48. Lee SS, Chung HY, Yu W (2010) Quality of life of long-term survivors after a distal subtotal gastrectomy. Cancer Res Treat 42:130–134

49. Wenger NK, Mattson ME, Furberg CD, Elinson J (1984) Assessment of quality of life in clinical trials of cardiovascular therapies. Am J Cardiol 54:908–913

50. Ware JE Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220–233

51. Group E (1990) EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16:199–208

52. Nieveen Van Dijkum EJ, Terwee CB, Oosterveld P, Van Der Meulen JH, Gouma DJ, De Haes JC (2000) Validation of the gastrointestinal quality of life index for patients with potentially operable periampullary carcinoma. Br J Surg 87:110–115

53. Svedlund J, Sjodin I, Dotzavall G (1988) GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33:129–134

Surg Endosc (2016) 30:1920–1929